August 20, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: **Press Release**

Ref: **Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed herewith the Press Release titled *"Dr. Lal PathLabs Pioneers AI Integration in Cancer Diagnosis in India".*

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl: As above

PRESS RELEASE

Dr. Lal PathLabs Pioneers AI Integration in Cancer Diagnosis in India

New Delhi, August 20, 2025 – In a pioneering move set to transform cancer diagnostics in India, **Dr. Lal PathLabs (DLPL)** has become the **first laboratory in the country** to adopt a deep learning-based **AI module to detect lymph node metastasis**, including micrometastasis, in cancer cases. This cutting-edge technology, validated in collaboration with **Qritive**, was showcased at **USCAP 2025** one of the world's leading pathology conferences.

Accurate identification of cancer spread to lymph nodes is vital in determining the stage and treatment path for patients. If the spread of cancer to the lymph nodes is left undetected, it can allow the disease to progress to later stages, increasing the risk of metastasis to distant organs and significantly reducing survival rates. Therefore, the identification of occult metastases in patients with early-stage cancer could have a substantial clinical impact on treatment planning and optimal therapy for patients with cancer.

Detecting micrometastases—tiny clusters of cancer cells in lymph nodes—usually takes a lot of time and special tests. The AI tool *QiAI Lymph Node Dx* changes that by using deep learning to quickly and accurately spot cancer cells on digital slides. Adding this technology to regular medical practice makes diagnosing cancer faster and more reliable.

Key Highlights:

- **100% Sensitivity & Negative Predictive Value:** The AI model detected all metastatic cases with no false negatives, making it a powerful screening tool.
- **Enhanced Accuracy:** Even single cancer cell metastasis was detected and later confirmed using immunohistochemistry.
- **Tumour Agnostic:** The AI module has been validated across multiple cancer types, including breast cancer (which accounts for approximately 28.2%[1] of cancer cases among women in India)—demonstrating its versatility and broad clinical applicability.
- **Clinical Benefit:** This leads to earlier, more accurate diagnoses—improving treatment decisions for patients.

"At Dr. Lal PathLabs, we are proud to lead the way in bringing AI-powered diagnostics to India," said **Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs**. *"This advanced technology allows us to identify cancer spread with exceptional precision and speed — particularly micrometastasis that may be missed by the human eye. By integrating AI into our pathology workflow, we are not only enhancing diagnostic accuracy but also enabling quicker clinical decisions, which can significantly improve treatment outcomes and quality of life for patients."*

The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases. It accurately detected single-cell and micrometastases that had been missed during manual reviews. These results were later validated through immunohistochemistry (IHC), confirming the system's reliability.

"The role of a pathologist is evolving rapidly, and we must evolve with it. Introducing AI into our diagnostic workflow is not just about adopting technology — it's about reimagining how we detect and respond to disease," said **Dr. Vandana Lal, Executive Director, Dr Lal PathLabs**. *"This*

---

[1] https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35188

advancement strengthens our ability to identify even the most elusive signs of cancer, like micrometastasis, with greater speed and certainty. It's a significant leap forward in how we serve our clinicians and patients, and a proud moment in our commitment to driving precision diagnostics in India.

Commenting on the development, **Mr. Bruno Occhipinti, CEO, Qritive Pte. Ltd.** said: *"We previously got the opportunity to collaborate with the team at Dr Lal PathLabs on a study, which resulted in the abstract presented at USCAP'25 in Boston. Following extensive testing and workflow validation, we are now excited to go live and enable the transformative impact of our AI-powered solution on critical diagnoses. This has the potential to unlock massive efficiency and accuracy gains in large volume settings, further enhancing Lal PathLabs' excellence in its operations."*

As cancer cases continue to rise, the integration of AI-powered diagnostic tools like QiAI Lymph Node Dx is expected to play a key role in transforming the accuracy and efficiency of cancer care in India.

***

About Dr. Lal PathLabs Limited:

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on March 31, 2025 the Company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

About Qritive:

Headquartered in Singapore, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes. Qritive leverages deep learning technology to support the interpretation of pathology biopsies for time and resource-strapped pathologists, enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

For more information, please connect with:

Chehak Mishra
Adfactors PR

+91 8505824666
Chehak.mishra@adfactorspr.com